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ABSTRACT 
Objective: The present study was undertaken to develop and validate an RP-HPLC method for the combination of imiquimod and salicylic acid 
Methods: The method was carried out on Nucleodur C18 (250 mm × 4.6 mm I.D., 5  m) using low-pressure gradient elution mode. The mobile 
phase was used as 30M potassium dihydrogen phosphate and acetonitrile (45:55) pH 6.5 adjusted using ortho-phosphoric acid. The concentration 
of solvents was 1-20 µg/ml and the volume of injection was 20 mcl with the flow rate of 1.0 ml/min. The absorption maxima of salicylic acid and 
imiquimod were found 234 nm and 226 nm, respectively. 
Results: The method was validated and showed the linearity greater than 0.99% and with precision (RSD%<1). The limit of detection (LOD) and 
limit of quantification (LOQ) of salicylic acid was found to be 0.09756 µg/ml and 0.2956 µg/ml, respectively, and imiquimod was found to be 
0.044031 µg/ml and 0.13334 µg/ml, respectively. 
Conclusion: The method developed in the present study was found to be sensitive, specific, and can be applied for the simultaneous estimation of 
imiquimod and salicylic acid. 
Keywords: Imiquimod, Salicylic acid, Reverse-phase high-performance liquid chromatography (RP-HPLC), Validation, International council for 
harmonization (ICH) 
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INTRODUCTION 
Imiquimod is chemically 1-(2-methyl propyl)-1H-imidazo [4, 5-c] 
quinolin-4-amine, which is a novel synthetic compound that is a 
member of the imidazoquinolone family of drugs [1]. The molecular 
formula of imiquimod is C14H16N4, which is a white crystalline 
powder and the molecular weight is 240.30g/mol. The solubility of 
imiquimod is freely soluble in oleic acid and lactic acid with melting 
point 292-294 °C and pKa value 2.7. Imiquimod is an immune 
response modifiers use in the treatment for external genital warts 
by the mechanism response modifier that acts as a toll-like receptor 
7 agonists. It does not kill the viruses that cause warts directly, 
however, also used to treat skin problems of face and scalp that is 
called actinic keratoses and also for various skin cancers called 
superficial basal cell carcinoma. In a present-day commercially 
available as Aldara® 5% imiquimod cream, approved by U. S. Food 
and Drug Administration (“FDA”) in 1997 [2-4]. 
 
 
Fig. 1: Chemical structure of imiquimod 
 
Salicylic acid (from latin salix, willow tree, from the bark of which 
the substance used to be obtained) is a monohydroxybenzoic acid, a 
type of phenolic acid and a beta hydroxy acid. Salicylic acid has the 
formula C6H4(OH) COOH, where the OH group is ortho to the 
carboxyl group and is poorly soluble in water (2 g/l at 20 °C). 
Aspirin (acetylsalicylic acid or ASA) can be prepared by the 
esterification of the phenolic hydroxyl group of salicylic acid with 
the acetyl group from acetic anhydride or acetyl chloride. The 
compound is white crystalline powder and the molecular weight is 
138.12 g/mol. The solubility of salicylic acid is good in ether, CCl4, 
benzene, propanol, acetone, ethanol, oil of turpentine, toluene [5, 6]. 
It shows its anti-inflammatory action by suppressing the activity of 
cyclooxygenase (COX), an enzyme that is responsible for the 
production of pro-inflammatory mediators such as the 
prostaglandins [7]. Salicylic acid also has its anti-acne action [8]. 
Chemical structure of salicylic acid is given below:  
 
 
Fig. 2: Chemical structure of salicylic acid 
 
Simultaneously steps were taken for these two drugs successfully. 
Therefore it was thought to develop an accurate and rapid RP-HPLC 
method for simultaneous estimation of the combination of imiquimod 
and salicylic acid. This method was validated as per the current 
International Conference on Harmonization (ICH) guideline [9-11]. 
MATERIALS AND METHODS 
Salicylic acid was procured as a gift sample from SGPTC Pvt. Ltd and 
imiquimod drug was obtained as a gift sample from Glenmark 
Pharma, Mumbai India. All other chemicals like o’phosphoric acid, 
potassium dihydrogen phosphate, and disodium hydrogen 
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orthophosphate were used of AR grade and solvents like methanol, 
acetonitrile, and water were used of HPLC grade 
Identification of standard drugs 
The identification of standard drugs was carried out by melting 
point study, infrared spectroscopic study, and solubility study. 
Rp-hplc method 
Selection of detection wavelength 
A known concentration of 10 μg/ml of salicylic acid and imiquimod 
were prepared in methanol and scanned in the UV region 200-400 nm.  
Selection of mobile phase and optimization of chromatographic 
condition 
Initially, the mobile phase was tried with methanol: water, 
acetonitrile: water, acetonitrile: water: methanol and then finally 
with phosphate buffer: acetonitrile: at various pH conditions. The 
following optimized parameters were used as a final method for the 
simultaneous estimation of salicylic acid and imiquimod. 
Chromatographic condition 
In the optimized parameters, the stationary phase was Nucleodur 
C18 (250 mm × 4.6 mm I.D., 5  m) using low-pressure gradient 
elution mode. 30M potassium dihydrogen phosphate and 
acetonitrile (45:55) pH 6.5 were used as mobile phase and pH were 
adjusted using orthophosphoric acid. The concentration of solvents 
was 1-20 µg/ml, and the volume of injection was 20 µl with the flow 
rate of 1.0 ml/min. The absorption maxima of salicylic acid and 
imiquimod were set in 234 nm and 226 nm, respectively. 
Standard stock solution preparation (100 μg/ml) 
100 μg/ml solution was prepared using 10 mg of salicylic acid 1 mg 
of imiquimod and about 1 ml of diluent was added and sonicate to 
dissolve to make the standard solution. 
Preparation of calibration curve  
Different concentration was prepared 0.1 μg/ml to 1 μg/ml for 
imiquimod and 1 µg/ml to 10 µg/ml for salicylic acid from the 
standard stock solution, respectively. 
Validation of RP-HPLC method 
Linearity 
Different concentrations of both the drugs were prepared for 
linearity i.e. salicylic acid 1-10 μg/ml and imiquimod 0.1-1 μg/ml 
[12, 13]. 
Accuracy 
Recovery studies were carried out by the addition of standard 
drug solution at the level of 80%, 100%, and 120% to the pre-
analyzed sample. Results of the recovery study were found to be 
within the acceptance criteria 100±10 %. In this method, the 
known concentration of standard drug was added to the assay 
sample [14, 15]. 
Precision 
Different concentrations of both the drugs were used for intra-day 
and inter-day variation for six times in the same day. The 
concentration was 5 μg/ml of salicylic acid and 0.5 μg/ml 
imiquimod, and then % RSD was calculated [16, 17]. 
Limit of detection and limit of quantification 
The limit of detection can be calculated using the following equation 
as per ICH guidelines [18]. 
    = 3.3 ×    ⁄  
Where N is the standard deviation of the intercepts of the drug, and 
S is the slope of the corresponding calibration curve. 
The limit of quantification can be calculated using the following 
equation as per ICH guidelines. 
LOQ = 10 × N S⁄  
Where N is the standard deviation of the intercepts of the drug, and 
S is the slope of the corresponding calibration curve [19]. 
Robustness 
Same samples of salicylic acid and imiquimod concentration 5μg/ml 
and 0.5μg/ml respectively by considered variation in the method 
parameters i.e. change in wavelength or change in flow rate, change 
in pH of the mobile phase. The change in the responses of salicylic 
acid and imiquimod were noted in terms of %RSD [20]. 
Specificity 
The specificity of the HPLC method was demonstrated by the 
separation of the analytes from other potential components such as 
impurities, degradants, or excipients. A volume of 20μl of individual 
ingredients and excipients solution was injected and the 
chromatogram was recorded [21]. 
Ruggedness 
The ruggedness was studied by analyzing the same samples of 
salicylic acid and imiquimod concentration 5μg/ml and 0.5μg/ml, 
respectively by changing the analyst. The change in the responses of 
salicylic acid and imiquimod were noted in terms of %RSD [22]. 
RESULTS AND DISCUSSION  
Identification of imiquimod and salicylic acid 
Salicylic acid and imiquimod were observed for organoleptic 
properties like physical appearance, odor, and melting point. The 
drugs were identified with the help of UV and FTIR, and exhibited 
absorption maxima was 234 nm for salicylic acid and 226 nm for 
imiquimod when methanol was used as a solvent as mentioned in 
the literature (fig. 3). 
 
 
Fig. 3: UV spectrum of salicylic acid (A) and imiquimod (B) in methanol 
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The linearity of both the drugs was found within acceptance criteria. 
The correlation coefficient (r2) obtained was calculated and it was 
found to be greater than 0.99 for salicylic acid and imiquimod is 
given in the below table, which is well within the acceptance criteria. 
Good linearity with the coefficient of correlation 0.99 indicated that 
the proposed method was linear within the range of 1 to 10 µg/ml, 
0.1 to 1 µg/ml, respectively for salicylic acid and imiquimod. 
 
Table 1: Linearity of salicylic acid 
Conc.(µg/ml) Area1 Area2 Area3 Mean SD %RSD 
1 55346 55051 55866 55421 412.6439 0.744562 
2 94156 94907 94550 94537.67 375.6519 0.397357 
3 129106 125734 124812 126550.7 2260.491 1.786234 
4 162548 165085 167974 165202.3 2714.902 1.64338 
5 187989 189886 194048 190641 3099.256 1.625703 
6 230434 236106 231690 232743.3 2979.099 1.279993 
7 267238 268739 264993 266990 1885.274 0.706121 
8 304641 308556 307314 306837 2000.613 0.652012 
9 342474 341383 348660 344172.3 3924.53 1.14028 
10 383247 388043 386828 386039.3 2493.371 0.645885 
*Conc. = concentration, mean±SD, n=3, SD = standard deviation, RSD = relative standard deviation 
 
Table 2: Linearity of imiquimod 
Conc.(µg/ml) Area1 Area 2 Area 3 Mean SD %RSD 
0.1 100795 100900 100854 100849.7 52.63396 0.052191 
0.2 165045 165650 164071 164922 796.6536 0.483049 
0.3 225478 220799 227558 224611.7 3461.78 1.541229 
0.4 268053 266795 267947 267598.3 697.723 0.260735 
0.5 330441 336627 332784 333284 3123.163 0.937088 
0.6 395254 394840 397691 395928.3 1540.485 0.389082 
0.7 468121 469870 463485 467158.7 3299.488 0.706288 
0.8 522375 524480 525548 524134.3 1614.496 0.308031 
0.9 595412 595953 595245 595536.7 370.0977 0.062145 
1 655536 652236 651048 652940 2325.349 0.356135 
*Conc. = concentration, mean±SD, n=3, SD = standard deviation, RSD = relative standard deviation 






















































































































Fig. 6: Average 
Fig. 7: Chromatogram of 
Table 
Accuracy results of salicylic acid 
Conc. level Area Mean 
80% 167045 165052.66 
163972 
164141 
100% 183748 184728.33 
185458 
184979 
120% 215834 217098.66 
216921 
218541 
Accuracy results of imiquimod 
Conc. level Area Mean 
80% 261795 261930.33 
260825 
263171 
100% 319439 321252.33 
321026 
323292 
120% 375617 375861 
377201 
374765 
*Conc. = concentration, mean±SD, n=3, SD = standard deviation, RSD = relative standard
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linearity of salicylic acid (left) and imiquimod (right)
 
salicylic acid and imiquimod (4 μg/ml and 0.4 μg
 
3: Accuracy results of salicylic acid and imiquimod 
Amount added Amount recovered % Recovery
4 µg/ml 4.12 103.055 
4 µg/ml 4.03 100.932 
4 µg/ml 4.04 101.049 
5 µg/ml 4.58 91.674 
5 µg/ml 4.63 92.619 
5 µg/ml 4.61 92.354 
6 µg/ml 5.47 91.170 
6 µg/ml 5.50 91.671 
6 µg/ml 5.54 92.417 
Amount added Amount recovered % Recovery
0.4 µg/ml 0.369 92.39 
0.4 µg/ml 0.367 91.99 
0.4 µg/ml 0.371 92.95 
0.5 µg/ml 0.463 92.67 
0.5 µg/ml 0.465 93.18 
0.5 µg/ml 0.469 93.92 
0.6 µg/ml 0.555 92.45 
0.6 µg/ml 0.557 92.88 
0.6 µg/ml 0.553 92.22 
 deviation 
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The results indicate that the recoveries are well within the 
acceptance range of 80–120% (table 3). The chromatogram of 
salicylic acid and imiquimod drugs at level 80% was shown in fig. 8. 
Precision 
The %RSD for the area of six replicate injections was found to be 
within the specified limits i.e. for salicylic acid, it was 0.742393% 
and imiquimod it was observed 0.995204%. Whereas the % RSD for 
intra and inter-day precision of salicylic acid and imiquimod were 
observed below 2% [18-20]. The low values of % RSD indicate that 
the method is precise. % RSD for interday precision and intraday 
precision was given below that was found to be within the specified 
limits. 
Limit of detection and limit of quantitation  
The LOD was found to be 0.09756 µg/ml and 0.044031 µg/ml for 
salicylic acid and imiquimod respectively and LOQ was found to be 
0.2956 µg/ml and 0.13334 µg/ml salicylic acid and imiquimod 
respectively which showed that sensitivity of the method was high. 
Robustness 
The Percentage of RSD should not be more than 2. The %RSD 
obtained for change of flow rate, change in wavelength, and pH 
variation in the mobile phase was found to be below 2, which was 
within the acceptance criteria. Hence the method was robust. 
Ruggedness 
The results were found within a specified limit, % RSD was less than 
2. Data are tabulated in table 9 and fig. 10. 
Specificity 
Specificity of salicylic acid and imiquimod are shown in fig. 11 and 
table 10. All the data were within limits. %RSD of salicylic acid in 
specificity was observed 0.186425% and for imiquimod, it was 
0.384456%.
  
Table 4: Repeatability of salicylic acid and imiquimod 
S. No. Salicylic acid Imiquimod 
Conc.(µg/ml) Area Conc.(µg/ml) Area 
1 5 180729 0.5 312844 
2 5 180281 0.5 318685 
3 5 181842 0.5 311867 
4 5 182989 0.5 310441 
5 5 183886 0.5 316627 
6 5 182048 0.5 312784 
Mean 181962.5 Mean 313874.7 
Standard Deviation 1350.877 Standard Deviation 3123.692 
%RSD 0.742393 %RSD 0.995204 
*Mean for six independent analysis, mean±SD, n=6, Conc. = concentration, RSD = relative standard deviation 
 
Table 5: Intraday and intraday precision of salicylic acid and imiquimod 
Intraday precision 
S. No. Salicylic acid Imiquimod 
Conc.(µg/ml) Area Conc.(µg/ml) Area 
1 5 194588 0.5 371303 
2 5 194165 0.5 366835 
3 5 195142 0.5 369995 
4 5 194057 0.5 370772 
5 5 195544 0.5 368306 
6 5 194999 0.5 369934 
Mean 194749.2 Mean 313874.7 
Standard Deviation 582.2053 Standard Deviation 3123.692 
%RSD 0.298951 %RSD 0.995204 
Interday precision 
S. No. Salicylic acid Imiquimod 
 Conc.(µg/ml) Area  Conc.(µg/ml) 
1 5 192990 1 5 
2 5 193563 2 5 
3 5 193229 3 5 
4 5 193825 4 5 
5 5 193199 5 5 
6 5 193807 6 5 
Mean 193435.5 Mean 369890.8 
Standard Deviation 347.2819 Standard Deviation 2046.481 
%RSD 0.179534 %RSD 0.553266 
*Mean for six independent analysis, mean±SD, n=6, RSD = relative standard deviation 
 
Table 6: Limit of detection and quantitation 
API parameter Linearity 1 Linearity 2 Linearity 3 Intercept SD Slope mean LOD LOQ 
Salicylic acid Intercept 18267 19774 17719 1064.14112 35992.3333 0.09756 
µg/ml 
0.2956 
µg/ml Slope 35900 35722 36355 
Imiquimod Intercept 34160 34149 35575 820.144499 61466.3333 0.044031 
µg/ml 
0.13334 
µg/ml Slope 61543 61575 61281 
*mean±SD, n=3, LOD = limit of detection, LOQ = limit of quantitation 
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Fig. 9: Chromatogram of repeatability of salicylic acid and imiquimod 
 
Table 7: Robustness of salicylic acid and imiquimod at different flow rates and column temperature 
Change in flow rates  
Conc.(µg/ml) 0.690 ml/min 0.700 ml/min 0.710 ml/min 
Area Area Area 
Salicylic acid Imiquimod Salicylic acid Imiquimod Salicylic acid Imiquimod 
5, 0.5 185355 336750 185716 331298 179209 322635 
5, 0.5 186835 331907 185978 327514 180008 319692 
5, 0.5 184881 331433 185234 332858 181071 323943 
Mean 185690.333 333363.33 185642.7 330556.7 180096 322090 
SD 1019.24743 2942.4993 377.3822 2748.048 934.114 2177.273 
%RSD 0.54889634 0.8826704 0.203284 0.831339 0.518676 0.675983 
Change in column temperature 
Conc.(µg/ml) 35 °C 35 °C 35 °C 
Area Area Area 
Salicylic acid Imiquimod Salicylic acid Imiquimod Salicylic acid Imiquimod 
5, 0.5 183450 326827 189534 366900 190840 366438 
5, 0.5 182884 325182 194165 366835 193563 366114 
5, 0.5 187570 326333 193229 369038 195142 369995 
Mean 184634.667 326114 192309.3 367591 193181.66 367515.7 
SD 2557.77742 844.0835 2448.649 1253.56 2176.2036 2153.268 
%RSD 1.38531808 0.258831 1.273286 0.34102 1.1265063 0.585898 
*Conc. = concentration, mean±SD, n=3, SD = standard deviation, RSD = relative standard deviation 
 
Table 8: Robustness of salicylic acid and imiquimod at different mobile phase ratio and different wavelength 
Conc.(µg/ml) Buffer: ACN 49.9:50.1 Buffer: ACN 50.1:49.9 Buffer: ACN 50:50 
Area Area Area 
Salicylic acid Imiquimod Salicylic acid Imiquimod Salicylic acid Imiquimod 
5, 0.5 192990 371471 193807 370423 189534 366900 
5, 0.5 194999 369934 194057 370772 194165 366835 
5, 0.5 195544 368306 189264 368613 193229 369038 
Mean 194511 369903.7 192376 369936 192309.3 367591 
SD 1345.11598 1582.718 2697.968 1158.964 2448.648 1253.56 
%RSD 0.69153723 0.427873 1.402445 0.313288 1.273286 0.34102 
Change in wavelength  
Conc.(µg/ml) 222 nm 227 nm 232 nm 
Area Area Area 
Salicylic acid Imiquimod Salicylic acid Imiquimod Salicylic acid Imiquimod 
5, 0.5 167812 287540 185799 320120 147045 394888 
5, 0.5 168691 286264 184977 319351 147211 388641 
5, 0.5 167785 287674 183279 321442 146878 392983 
Mean 168096 287159.3 184685 320304.3 147044.66 391764.5 
SD 515.46192 778.2707 1285.126 1057.617 166.50025 4417.296 
%RSD 0.3066473 0.271024 0.695847 0.330191 0.11323107 1.127539 
*Conc. = concentration, mean±SD, n=3, ACN = acetonitrile, SD = standard deviation, RSD = relative standard deviation 
 
Table 9: Ruggedness study by analyst 1 and analyst 2 
Conc.(µg/ml) Analyst 1 Analyst 2 
Area Area 
Salicylic acid Imiquimod Salicylic acid Imiquimod 
5, 0.5 193825 371153 203497 386815 
5, 0.5 194588 371303 198780 384112 
5, 0.5 193199 371146 196176 380535 
Mean 193870.6667 371200.6667 199484.3333 383820.6667 
SD 695.6251385 88.69235223 3710.973502 3150.120051 
%RSD 0.358808865 0.023893371 1.860283181 0.820727054 
*Conc. = concentration, mean±SD, n=3, SD = standard deviation, %RSD = relative standard deviation 
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(A)       (B) 
Fig. 10: Chromatogram of salicylic acid and imiquimod by analyst 1 (A) and analyst 2 (B) 
 
Table 10: Specificity data of salicylic acid and imiquimod 
Conc.(µg/ml) Specificity 
Area 
Salicylic acid Imiquimod 
5, 0.5 189068 336047 
5, 0.5 188871 335741 
5, 0.5 189556 333678 
Mean 189165 335155.3 
SD 352.6514 1288.524 
%RSD 0.186425 0.384456 
*Conc. = concentration, mean±SD, n=3, SD = standard deviation, %RSD = relative standard deviation 
 
 
Fig. 11: Chromatogram of salicylic acid and imiquimod (specificity) 
 
CONCLUSION 
The RP-HPLC method was carried out on Nucleodur C18 (250 mm × 
4.6 mm I.D., 5  m) using low-pressure gradient elution mode. The 
limit of detection (LOD) and limit of quantification (LOQ) of salicylic 
acid was found to be 0.09756 µg/ml and 0.2956 µg/ml, respectively, 
and imiquimod was found to be 0.044031 µg/ml and 0.13334 µg/ml, 
respectively. The developed and validate method for imiquimod and 
salicylic acid was found to be sensitive, specific, and accurate and 
can be effectively applied for the simultaneous estimation of 
imiquimod and salicylic acid.  
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